Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | BRD2 | P25440 | 3/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934437 | 0.91 | HDAC1 (0.47) | PTGDR2FFAR1BRD4BRD2CREBBP | |
| SCHEMBL933913 | 0.89 | PTGDR2 (0.43) | PTGDR2FFAR1BRD4BRD2CREBBP | |
| SCHEMBL934534 | 0.82 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL934199 | 0.81 | PTGDR2 (0.56) | PTGDR2 | |
| SCHEMBL934124 | 0.80 | PTGDR2 (0.46) | PTGDR2 | |
| SCHEMBL951203 | 0.80 | PTGDR2 (0.52) | PTGDR2FFAR1BRD4BRD2CREBBP | |
| SCHEMBL2681202 | 0.79 | PTGDR2 (0.46) | PTGDR2HDAC1HDAC8HDAC6 | |
| SCHEMBL934130 | 0.79 | PTGDR2 (0.43) | PTGDR2HDAC1HDAC8HDAC6 | |
| SCHEMBL933907 | 0.79 | PTGDR2 (0.41) | PTGDR2NR3C2HDAC1HDAC8HDAC6 | |
| SCHEMBL933413 | 0.79 | ALDH1A1 (0.50) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PTGDR2 548/4885FFAR1 924/4885BRD4 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.